Glutathione limits RUNX2 oxidation and degradation to regulate bone formation

Area of Science:

• Biochemistry
• Cell Biology
• Skeletal Biology

Background:

• Reactive oxygen species (ROS) are byproducts of metabolism, and elevated levels negatively impact osteoblasts, contributing to aging and sex steroid deficiency-related bone issues.
• The precise mechanisms by which osteoblasts control ROS and how ROS inhibits their function remain unclear.

Purpose of the Study:

• To investigate the role of de novo glutathione (GSH) biosynthesis in neutralizing ROS within osteoblasts.
• To elucidate the mechanisms by which ROS affects osteoblast differentiation and bone formation, focusing on the RUNX2 protein.

Main Methods:

• Utilized a multifaceted approach to study the impact of GSH biosynthesis and ROS levels on osteoblast function.
• Employed genetic manipulation to alter GSH biosynthesis and utilized catalase to reduce ROS levels.
• Examined the stability of RUNX2 protein, osteoblast differentiation markers, and bone formation in vivo and in vitro.

Main Results:

• Reduced GSH biosynthesis led to RUNX2 degradation, impaired osteoblast differentiation, and decreased bone formation.
• Conversely, ROS reduction with catalase enhanced RUNX2 stability and promoted osteoblast differentiation, particularly when GSH biosynthesis was limited.
• In utero antioxidant therapy improved bone development in a mouse model of cleidocranial dysplasia.

Conclusions:

• De novo GSH biosynthesis is essential for maintaining a pro-osteogenic REDOX environment by neutralizing ROS.
• RUNX2 acts as a molecular sensor of the osteoblast REDOX state, with ROS negatively regulating its stability and osteogenic function.
• Targeting ROS through antioxidant therapy presents a potential therapeutic strategy for bone development disorders.